Pharmacovigilance System in Non-EU Countries

This chapter explores the landscape of pharmacovigilance systems in non-EU countries, shedding light on pharmacovigilance regulations in non-EU regions. It begins by introducing the role of pharmacovigilance in protecting health and emphasizes the variations between non-EU countries. While the EU has regulations, a harmonized approach, and centralized monitoring through the European Medicines Agency (EMA), non-EU countries have systems influenced by local factors. The following section examines pharmacovigilance systems in EU countries, starting with an overview of their regulatory landscape. It highlights authorities in non-EU regions, such as the FDA in the USA, Health Canada in Canada, TGA in Australia, PMDA in Japan, and CDSCO (Central Drugs Standard Control Organisation) in India, which play a significant role in ensuring drug safety and quality. Furthermore, this chapter outlines the differences in reporting adverse drug reactions (ADRs) pharmacovigilance guidelines, signal detection methods, communication strategies, and collaboration efforts in non-EU countries. These discrepancies arise from legislation, local policies, and international standardization initiatives. Ultimately, this chapter emphasizes that understanding these frameworks is crucial for compliance and effective drug safety monitoring.